Fighting counterfeit medicines in Europe: the effect on access to medicines

14 September 2017

Policy

The implementation of the Falsified Medicines Directive, and its Delegated […]

US FDA Advisory committee hears first-hand about the decade of EU experience with biosimilar medicines use

13 July 2017

Policy

Medicines for Europe Director General Adrian van de Hoven participated […]

Medicines for Europe Country Specific Market Access Policies

23 May 2017

Policy

Essential Medicines for Universal Health Coverage

7 November 2016

Policy

Medicines for Europe’s Contribution to WHO’s Biological Qualifier (BQ) Developments (PRESENTATION and SPEECH)

18 October 2016

Policy

      18 October 2016 Suzette Kox Senior Director […]

Understanding the Science of Extrapolation and Defining Interchangeability – Dr. Elena Wolff-Holz, EULAR Symposium London

10 June 2016

Policy

EGA-EBG Summary Position Regarding the WHO Biologic Qualifier Proposal (INN Working Doc. 14.342)

21 March 2016

Policy

Biosimilar Product Labelling

2 February 2016

Policy

EGA-EBG Considerations on WHO’s BQ Proposal – Suzette Kox, WHO INN Open Session with Stakeholders, Geneva, 13 October 2015 (PPT)

13 October 2015

Policy

Investing in People Centred Health Service Delivery – Paul Cornes, Riga Health Conference – How to Improve Health Systems Through Technology? 29-30 June 2015, Riga, Latvia (PPT)

29 June 2015

Policy